NAYA Biosciences (NAYA) Stock Price, News & Analysis

Company Overview

NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases and fertility. NAYA Biosciences, formerly known as INVO BIOSCIENCE, is based in SARASOTA, Fla.

Key Stats

• Today's Range: $1.25 to $1.29
• 50-Day Range: $1.26 to $2.39
• 52-Week Range: $1.38 to $17.04
• Volume: 103,557 shs
• Average Volume: 53,151 shs
• Market Capitalization: $839.16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

NAYA Stock Analysis - Frequently Asked Questions

How have NAYA shares performed this year?

NAYA Biosciences' stock was trading at $9.72 on January 1st, 2025. Since then, NAYA stock has decreased by 87.0% and is now trading at $1.26.
View the best growth stocks for 2025 here.

When did NAYA Biosciences' stock split?

NAYA Biosciences shares reverse split on Tuesday, March 18th 2025. The 1-12 reverse split was announced on Thursday, March 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of NAYA Biosciences?

Shares of NAYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/19/2025
• Next Earnings (Estimated): 6/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NAYA
• CIK: 1417926
• Web: www.invobioscience.com
• Phone: 978-878-9505
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $24.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +1,804.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.03 million
• Net Margins: -119.91%
• Pretax Margin: -119.01%
• Return on Equity: N/A
• Return on Assets: -41.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.23
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: $6.23 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.06) per share
• Price / Book: -0.61

Miscellaneous

• Outstanding Shares: 666,000
• Free Float: 4,396,000
• Market Cap: $839.16 thousand
• Optionable: N/A
• Beta: 2.03